Rafael Holdings, Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Rafael Holdings, Inc. on October 28, 2021. The filing discloses material updates regarding the clinical development of the company's lead product candidate, CPI-613 (devimistat), specifically concerning two Phase 3 trials: AVENGER 500 in metastatic pancreatic cancer and ARMADA 2000 in relapsed or refractory acute myeloid leukemia (AML).
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on clinical trial outcomes and regulatory disclosures.
Material Changes and Clinical Outcomes
- AVENGER 500 Trial (Pancreatic Cancer): The Phase 3 trial for CPI-613 in patients with metastatic adenocarcinoma of the pancreas did not meet its primary endpoint of significant improvement in overall survival.
- ARMADA 2000 Trial (AML): Following a pre-specified interim analysis, the independent data monitoring committee recommended stopping the Phase 3 trial for patients with relapsed or refractory acute myeloid leukemia due to a lack of efficacy.
Outlook, Risks, and Management Commentary
The filing serves as a Regulation FD disclosure and an "Other Event" notification. The primary risk highlighted is the failure of the company's lead asset to demonstrate efficacy in two critical Phase 3 studies. The filing explicitly states that the information contained in the report and the attached press release (Exhibit 99.1) is not deemed "filed" with the SEC and will not be incorporated by reference into other filings.
Key Facts for Investor Verification
- Verify the full text of the press release (Exhibit 99.1) for detailed statistical data regarding the trial failures.
- Assess the impact of these negative results on the company's remaining cash runway and potential need for capital raising.
- Review subsequent filings for any updates on the strategic direction of the CPI-613 program or other pipeline assets.
- Confirm the status of the ARMADA 2000 trial termination and any regulatory communications with the FDA.